Health-claim substantiation (EFSA 13/14)

Health-claim substantiation prepares the scientific and clinical evidence dossier required to support a food, supplement, or nutraceutical health claim under the EU’s Article 13/14 framework (EFSA Regulation 1924/2006) or equivalent national health-claim regimes. A health claim — “supports immune function,” “reduces cholesterol absorption” — cannot be marketed in the EU without a substantiated, EFSA-reviewed evidence base, making this a genuine regulatory-compliance service distinct from general food-safety testing. The confirmed vendor base spans a range of positioning: a large generic testing/certification conglomerate with nutrition-science capability, a dedicated EU health-claim regulatory consultancy, and a North American firm spanning regulatory strategy through clinical trial execution.

The key directions of health-claim substantiation are:

1. Article 13/14 dossier preparation: compiling the scientific evidence base required for EFSA’s general-function (Article 13) or disease-risk-reduction (Article 14) health-claim categories.
2. Clinical trial design and execution for claim support: running the human clinical studies needed to generate claim-supporting evidence where existing literature is insufficient.
3. Regulatory strategy from concept to filing: advising a client from initial claim concept through the full EFSA submission and review process.
4. Cross-jurisdictional claim harmonization: adapting a substantiated claim for multiple regulatory regimes (EU, US FDA, other national frameworks) from a shared evidence base.

Sectoral value chain#

[Claim concept development] ──> [Evidence gap analysis] ──> [Clinical trial execution] ──> [Dossier compilation]
                                                                        │
                                                              (EFSA submission)
                                                                        │
                                                                        ▼
[Claim market authorization] <─── [Regulatory review response] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Systematic literature review methodology: structured evidence-review techniques required to assess a claim’s existing scientific support.
• Clinical trial design for regulatory claims: trial design specifically oriented toward generating EFSA-acceptable evidence rather than general research publication.
• Regulatory dossier formatting expertise: the specific documentation and formatting knowledge required for an EFSA-compliant submission.

The category’s core capability is scientific and regulatory expertise applied to evidence generation and dossier preparation, rather than a physical technology.

1. Regulatory-strategy-to-clinical-execution integration:
   • Nutrasource’s documented work with DSM-Firmenich spans from initial regulatory strategy through actual clinical trial execution, reflecting a full-service model rather than dossier-writing alone.
2. Large-conglomerate nutrition-science capability:
   • Intertek’s scale as a testing/certification conglomerate gives it broad laboratory and scientific-review capacity applicable to health-claim substantiation, distinct from a boutique regulatory consultancy’s narrower focus.
3. Dedicated EU market-entry regulatory strategy:
   • Care Europe’s positioning specifically around EU nutraceutical market entry reflects the jurisdiction-specific expertise health-claim substantiation requires, since EFSA’s Article 13/14 framework is distinct from other national regimes.